Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- And papillomaviruses and non-viral induced neoplasia

Antiviral Research

Volumn 114, Issue , 2015, Pages 21-46

  Andrei, G ^a   Topalis, D ^a   De Schutter, T ^a   Snoeck, R ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Acyclic nucleoside phosphonates; Cidofovir; Human papillomavirus; Human polyomaviruses; Non viral induced neoplasias; PMEG

Indexed keywords

ACYCLIC NUCLEOSIDE; CIDOFOVIR; DNA POLYMERASE; DOUBLE STRANDED DNA; GLYCOPROTEIN E1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHONIC ACID DERIVATIVE; PROBENECID; PROTEIN E7; PROTEIN P53; RABACFOSADINE; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR E2F; VIRUS PROTEIN; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CYTOSINE;

ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HEMANGIOMA; CERVICAL CANCER CELL LINE; DNA REPLICATION; DNA TUMOR VIRUS; DRUG MECHANISM; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; MERKEL CELL TUMOR; NEOPLASM; NONHUMAN; OFF LABEL DRUG USE; PAPILLOMA; PAPILLOMA VIRUS; POLYOMA VIRUS; PROTEIN EXPRESSION; RISK FACTOR; SARCOIDOSIS; STEROID THERAPY; THERAPY; TUMOR VOLUME; VIRUS GENOME; VIRUS REPLICATION; WART VIRUS; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; TUMOR CELL LINE; VIROLOGY;

CYTOMEGALOVIRUS; DNA VIRUSES; HUMAN HERPESVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE; POLYOMAVIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSINE; HUMANS; NEOPLASMS; ORGANOPHOSPHONATES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84916887089     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.10.012     Document Type: Review

References (217)

1. Abdulkarim, B., Bourhis, J., 2001. Antiviral approaches for cancers related to Epstein-Barr virus and human papillomavirus. Lancet Oncol. 2, 622-630.
2. Abdulkarim, B., Sabri, S., Deutsch, E., Chagraoui, H., Maggiorella, L., Thierry, J., Eschwege, F., Vainchenker, W., Chouaib, S., Bourhis, J., 2002. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 21, 2334-2346.
3. Abdulkarim, B., Sabri, S., Zelenika, D., Deutsch, E., Frascogna, V., Klijanienko, J., Vainchenker, W., Joab, I., Bourhis, J., 2003. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene 22, 2260-2271.
4. Amine, A., Rivera, S., Opolon, P., Dekkal, M., Biard, D.S., Bouamar, H., Louache, F., McKay, M.J., Bourhis, J., Deutsch, E., Vozenin-Brotons, M.C., 2009. Novel antimetastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. PLoS One 4, e5018.
5. Amine, A., Vozenin-Brotons, M.C., Abdulkarim, B., Violot, D., Aubel, C., Bourhis, J., 2006. Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines. Radiat. Res. 166, 600-610.
6. An, P., Saenz Robles, M.T., Pipas, J.M., 2012. Large T antigens of polyomaviruses: amazing molecular machines. Annu. Rev. Microbiol. 66, 213-236.
7. Andrei, G., Snoeck, R., 2010. Cidofovir activity against poxvirus infections. Viruses 2, 2803-2830.
8. Andrei, G., Snoeck, R., Piette, J., Delvenne, P., De Clercq, E., 1998a. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 10, 523-531.
9. Andrei, G., Snoeck, R., Piette, J., Delvenne, P., De Clercq, E., 1998b. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice. Oncol. Res. 10, 533-539.
10. Andrei, G., Snoeck, R., Schols, D., De Clercq, E., 2000. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol. Res. 12, 397-408.
11. Andrei, G., Snoeck, R., Vandeputte, M., De Clercq, E., 1997. Activities of various compounds against murine and primate polyomaviruses. Antimicrob. Agents Chemother. 41, 587-593.
12. Andres, C., Belloni, B., Puchta, U., Sander, C.A., Flaig, M.J., 2010. Prevalence of MCPyV in Merkel cell carcinoma and non-MCC tumors. J. Cutan. Pathol. 37, 28-34.
13. Arora, R., Chang, Y., Moore, P.S., 2012. MCV and Merkel cell carcinoma: a molecular success story. Curr. Opin. Virol. 2, 489-498.
14. Ashok, A., Atwood, W.J., 2006. Virus receptors and tropism. Adv. Exp. Med. Biol. 577, 60-72.
15. Atkin, S.J., Griffin, B.E., Dilworth, S.M., 2009. Polyoma virus and simian virus 40 as cancer models: history and perspectives. Semin. Cancer Biol. 19, 211-217.
16. Babel, N., Volk, H.D., Reinke, P., 2011. BK polyomavirus infection and nephropathy: the virus-immune system interplay. Nat. Rev. Nephrol. 7, 399-406.
17. Banerjee, N.S., Wang, H.K., Broker, T.R., Chow, L.T., 2011. Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes. J. Biol. Chem. 286, 15473-15482.
18. Belnap, D.M., Olson, N.H., Cladel, N.M., Newcomb, W.W., Brown, J.C., Kreider, J.W., Christensen, N.D., Baker, T.S., 1996. Conserved features in papillomavirus and polyomavirus capsids. J. Mol. Biol. 259, 249-263.
19. Bennett, S.M., Broekema, N.M., Imperiale, M.J., 2012. BK polyomavirus: emerging pathogen. Microbes Infect. 14, 672-683.
20. Bergvall, M., Melendy, T., Archambault, J., 2013. The E1 proteins. Virology 445, 35-56.
21. Bernard, H.U., Burk, R.D., Chen, Z., van Doorslaer, K., zur Hausen, H., de Villiers, E.M., 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401, 70-79.
22. Bernhoff, E., Gutteberg, T.J., Sandvik, K., Hirsch, H.H., Rinaldo, C.H., 2008. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am. J. Transplant. 8, 1413-1422.
23. Birkus, G., Kutty, N., Frey, C.R., Shribata, R., Chou, T., Wagner, C., McDermott, M., Cihlar, T., 2011. Role of cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191. Antimicrob. Agents Chemother. 55, 2166-2173.
24. Bodily, J., Laimins, L.A., 2011. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 19, 33-39.
25. Bonatti, H., Aigner, F., De Clercq, E., Boesmueller, C., Widschwendner, A., Larcher, C., Margreiter, R., Schneeberger, S., 2007. Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl. Int. 20, 238-246.
26. Burk, R.D., Harari, A., Chen, Z., 2013. Human papillomavirus genome variants. Virology 445, 232-243.
27. Calisto, D., Arcangeli, F., 2003. Topical cidofovir for condylomata acuminata of the genitalia in a 3-year-old child. J. Am. Acad. Dermatol. 49, 1192-1193.
28. Carter, J.J., Daugherty, M.D., Qi, X., Bheda-Malge, A., Wipf, G.C., Robinson, K., Roman, A., Malik, H.S., Galloway, D.A., 2013. Identification of an overprinting gene in Merkel cell polyomavirus provides evolutionary insight into the birth of viral genes. Proc. Natl. Acad. Sci. U.S.A. 110, 12744-12749.
29. Cesaro, S., Pillon, M., Tridello, G., Aljurf, M., Martino, R., Schroyens, W., Nozzoli, C., Barba, P., Faraci, M., Fagioli, F., Cappelli, B., Cordonnier, C., Al Mohareb, F., Floisand, Y., Greil, J., Panizzolo, I.S., Santarone, S., 2013. Relationship between clinical and BK virological response in patients with late hemorrhagic cystitis treated with cidofovir: a retrospective study from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 48, 809-813.
30. Chang, Y., Moore, P.S., 2012. Merkel cell carcinoma: a virus-induced human cancer. Annu. Rev. Pathol. 7, 123-144.
31. Cheng, J., DeCaprio, J.A., Fluck, M.M., Schaffhausen, B.S., 2009. Cellular transformation by Simian Virus 40 and Murine Polyoma Virus T antigens. Semin. Cancer Biol. 19, 218-228.
32. Chow, L.T., Broker, T.R., 2013. Human papillomavirus infections warts or cancer? Cold Spring Harb. Perspect. Biol. 5.
33. Chow, L.T., Broker, T.R., Steinberg, B.M., 2010. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 118, 422-449.
34. Christensen, N.D., Cladel, N.M., Hu, J., Balogh, K.K., 2014. Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model. Antiviral Res. 108, 148-155.
35. Cihlar, T., Chen, M.S., 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50, 1502-1510.
36. Cihlar, T., Ho, E.S., Lin, D.C., Mulato, A.S., 2001. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides, Nucleotides Nucleic Acids 20, 641-648.
37. Cihlar, T., Lin, D.C., Pritchard, J.B., Fuller, M.D., Mendel, D.B., Sweet, D.H., 1999. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. 56, 570-580.
38. Collette, D.C., Zechel, M.A., 2011. Novel treatment of atypical human papillomavirus-associated epithelial hyperplasia with cidofovir. J. Oral Maxillofac. Surg. 69, 2383-2386.
39. Compton, M.L., Toole, J.J., Paborsky, L.R., 1999. 9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cpr-PMEDAP) as a prodrug of 9-(2-phosphonylmethoxyethyl)guanine (PMEG). Biochem. Pharmacol. 58, 709-714.
40. Coremans, G., Snoeck, R., 2009. Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions. Expert Opin. Pharmacother. 10, 1343-1352.
41. Coupe, V.M., Gonzalez-Barreiro, L., Gutierrez-Berzal, J., Melian-Boveda, A.L., Lopez-Rodriguez, O., Alba-Dominguez, J., Alba-Losada, J., 2012. Transcriptional analysis of human papillomavirus type 16 in histological sections of cervical dysplasia by in situ hybridisation. J. Clin. Pathol. 65, 164-170.
42. Cubie, H.A., 2013. Diseases associated with human papillomavirus infection. Virology 445, 21-34.
43. Cundy, K.C., 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36, 127-143.
44. Cundy, K.C., Bidgood, A.M., Lynch, G., Shaw, J.P., Griffin, L., Lee, W.A., 1996. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos. 24, 745-752.
45. D'Abramo, C.M., Archambault, J., 2011. Small molecule inhibitors of human papillomavirus protein-protein interactions. Open Virol. J. 5, 80-95.
46. Dalianis, T., Hirsch, H.H., 2013. Human polyomaviruses in disease and cancer. Virology 437, 63-72.
47. Darwich, E., Darwich, L., Canadas, M.P., Klaustermeier, J., Ercilla, G., Alsina-Gibert, M., Mascaro Jr., J.M., 2011. New human papillomavirus (HPV) types involved in epidermodysplasia verruciformis (EV) in 3 HIV-infected patients: response to topical cidofovir. J. Am. Acad. Dermatol. 65, 43-45.
48. De Clercq, E., 2003. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16, 569-596.
49. De Clercq, E., 2006. Acyclic nucleoside phosphonates: Past, present and future Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: The phosphonate bridge. Biochem. Pharmacol. 73, 911-922.
50. De Clercq, E., 2007. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res. 75, 1-13.
51. De Clercq, E., 2011. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond. Biochem. Pharmacol. 82, 99-109.
52. De Clercq, E., Holy, A., 2005. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4, 928-940.
53. De Luca, A., Ammassari, A., Pezzotti, P., Cinque, P., Gasnault, J., Berenguer, J., Di Giambenedetto, S., Cingolani, A., Taoufik, Y., Miralles, P., Marra, C.M., Antinori, A., 2008. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 22, 1759-1767.
54. De Luca, A., Fantoni, M., Tartaglione, T., Antinori, A., 1999. Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 52, 891-892.
55. De Luca, A., Giancola, M.L., Ammassari, A., Grisetti, S., Cingolani, A., Paglia, M.G., Govoni, A., Murri, R., Testa, L., Monforte, A.D., Antinori, A., 2000. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 14, 117-121.
56. De Raedt, S., Lacor, P., Michotte, A., Flamez, A., Ebinger, G., 2008. Progressive multifocal leukoencephalopathy as first manifestation of sarcoidosis. Clin. Neurol. Neurosurg. 110, 186-189.
57. De Schutter, T., Andrei, G., Topalis, D., Duraffour, S., Mitera, T., Naesens, L., van den, O.J., Matthys, P., Snoeck, R., 2013a. Cidofovir treatment improves the pathology caused by the growth of human papillomavirus-positive cervical carcinoma xenografts in athymic nude mice. Cancer Lett 329, 137-145.
58. De Schutter, T., Andrei, G., Topalis, D., Duraffour, S., Mitera, T., van den, O.J., Matthys, P., Snoeck, R., 2013b. Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir. Mol. Cancer 12, 158.
59. De Schutter, T., Andrei, G., Topalis, D., Naesens, L., Snoeck, R., 2013c. Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC Med. Genomics 6, 18.
60. de Villiers, E.M., Fauquet, C., Broker, T.R., Bernard, H.U., Zur, H.H., 2004. Classification of papillomaviruses. Virology 324, 17-27.
61. Deberne, M., Levy, A., Mondini, M., Dessen, P., Vivet, S., Supiramaniam, A., Vozenin, M.C., Deutsch, E., 2013. The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenografts. Anticancer Drugs 24, 599-608.
62. DeCaprio, J.A., 2014. Human papillomavirus type 16 E7 perturbs DREAM to promote cellular proliferation and mitotic gene expression. Oncogene 33, 4036-4038.
63. DeCaprio, J.A., Garcea, R.L., 2013. A cornucopia of human polyomaviruses. Nat. Rev. Microbiol. 11, 264-276.
64. Derkay, C.S., Volsky, P.G., Rosen, C.A., Pransky, S.M., McMurray, J.S., Chadha, N.K., Froehlich, P., 2013. Current use of intralesional cidofovir for recurrent respiratory papillomatosis. Laryngoscope 123, 705-712.
65. Derkay, C.S., Wiatrak, B., 2008. Recurrent respiratory papillomatosis: a review. Laryngoscope 118, 1236-1247.
66. DiMaio, D., Petti, L.M., 2013. The E5 proteins. Virology 445, 99-114.
67. Donne, A.J., Hampson, L., He, X.T., Rothera, M.P., Homer, J.J., Hampson, I.N., 2007. Effects of cidofovir on a novel cell-based test system for recurrent respiratory papillomatosis. Head Neck 29, 741-750.
68. Donne, A.J., Hampson, L., He, X.T., Rothera, M.P., Homer, J.J., Hampson, I.N., 2009. Cidofovir induces an increase in levels of low-risk and high-risk HPV E6. Head Neck 31, 893-901.
69. Doorbar, J., Ely, S., Sterling, J., McLean, C., Crawford, L., 1991. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 352, 824-827.
70. Doorbar, J., Quint, W., Banks, L., Bravo, I.G., Stoler, M., Broker, T.R., Stanley, M.A., 2012. The biology and life-cycle of human papillomaviruses. Vaccine 30 (Suppl. 5), F55-F70.
71. Duensing, S., Munger, K., 2004. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int. J. Cancer 109, 157-162.
72. Ehlers, B., Wieland, U., 2013. The novel human polyomaviruses HPyV6, 7, 9 and beyond. APMIS 121, 783-795.
73. Eisen, D.P., Fraser, I.R., Sung, L.M., Finlay, M., Bowden, S., O'Connell, H., 2009. Decreased viral load and symptoms of polyomavirus-associated chronic interstitial cystitis after intravesical cidofovir treatment. Clin. Infect. Dis. 48, 86-88.
74. Fanning, E., Zhao, X., Jiang, X., 2009. Polyomavirus life cycle. In: Damania, B., Pipas, J.M. (Eds.), DNA Tumor Viruses. Springer Science and Business Media, New York, NY, pp. 1-24.
75. Farasati, N.A., Shapiro, R., Vats, A., Randhawa, P., 2005. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 79, 116-118.
76. Feltkamp, M.C., Kazem, S., van der, M.E., Lauber, C., Gorbalenya, A.E., 2013. From Stockholm to Malawi: recent developments in studying human polyomaviruses. J. Gen. Virol. 94, 482-496.
77. Feng, H., Shuda, M., Chang, Y., Moore, P.S., 2008. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319, 1096-1100.
78. Field, S., Irvine, A.D., Kirby, B., 2009. The treatment of viral warts with topical cidofovir 1%: our experience of seven paediatric patients. Br. J. Dermatol. 160, 223-224.
79. Fradet-Turcotte, A., Morin, G., Lehoux, M., Bullock, P.A., Archambault, J., 2010. Development of quantitative and high-throughput assays of polyomavirus and papillomavirus DNA replication. Virology 399, 65-76.
80. Franek, F., Holy, A., Votruba, I., Eckschlager, T., 1999. Acyclic nucleotide analogues suppress growth and induce apoptosis in human leukemia cell lines. Int. J. Oncol. 14, 745-752.
81. Frey, C.R., Andrei, G., Votruba, I., Cannizzaro, C., Han, B., Fung, W., Hung, M., Liu, X., Geleziunas, R., Fiten, P., Opdenakker, G., Snoeck, R., Cihlar, T., 2013. Mutations in adenosine deaminase-like (ADAL) protein confer resistance to the antiproliferative agents N6-cyclopropyl-PMEDAP and GS-9219. Anticancer Res. 33, 1899-1912.
82. Ganguly, N., Clough, L.A., Dubois, L.K., Mcguirk, J.P., Abhyankar, S., Aljitawi, O.S., O'Neal, N., Divine, C.L., Ganguly, S., 2010. Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach. Transpl. Infect. Dis. 12, 406-411.
83. Gaziev, J., Paba, P., Miano, R., Germani, S., Sodani, P., Bove, P., Perno, C.F., Marziali, M., Gallucci, C., Isgro, A., Paciaroni, K., Roveda, A., Simone, M.D., De Angelis, G., Alfieri, C., Lucarelli, G., 2010. Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir. Biol. Blood Marrow Transplant 16, 662-671.
84. Ghittoni, R., Accardi, R., Hasan, U., Gheit, T., Sylla, B., Tommasino, M., 2010. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 40, 1-13.
85. Gjoerup, O., Chang, Y., 2010. Update on human polyomaviruses and cancer. Adv. Cancer Res. 106, 1-51.
86. Gormley, R.H., Kovarik, C.L., 2012. Human papillomavirus-related genital disease in the immunocompromised host: Part II. J. Am. Acad. Dermatol. 66, 883.
87. Gosert, R., Rinaldo, C.H., Wernli, M., Major, E.O., Hirsch, H.H., 2011. CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes. Antimicrob. Agents Chemother. 55, 2129-2136.
88. Granot, R., Lawrence, R., Barnett, M., Masters, L., Rodriguez, M., Theocharous, C., Pamphlett, R., Hersch, M., 2009. What lies beneath the tent? JC-virus cerebellar granule cell neuronopathy complicating sarcoidosis. J. Clin. Neurosci. 16, 1091-1092.
89. Graupp, M., Gugatschka, M., Kiesler, K., Reckenzaun, E., Hammer, G., Friedrich, G., 2013. Experience of 11 years use of cidofovir in recurrent respiratory papillomatosis. Eur. Arch. Otorhinolaryngol. 270, 641-646.
90. Hadaczek, P., Ozawa, T., Soroceanu, L., Yoshida, Y., Matlaf, L., Singer, E., Fiallos, E., James, C.D., Cobbs, C.S., 2013. Cidofovir: a novel antitumor agent for glioblastoma. Clin. Cancer Res. 19, 6473-6483.
91. Hajek, M., Cvilink, V., Votruba, I., Holy, A., Mertlikova-Kaiserova, H., 2010. Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP. Eur. J. Pharmacol. 643, 6-12.
92. Hajek, M., Matulova, N., Votruba, I., Holy, A., Tloust'ova, E., 2005. Inhibition of human telomerase by diphosphates of acyclic nucleoside phosphonates. Biochem. Pharmacol. 70, 894-900.
93. Hatse, S., Naesens, L., De Clercq, E., Balzarini, J., 1999a. N6-cyclopropyl-PMEDAP: a novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties. Biochem. Pharmacol. 58, 311-323.
94. Hatse, S., Schols, D., De Clercq, E., Balzarini, J., 1999b. 9-(2-Phosphonylmethoxyethyl)adenine induces tumor cell differentiation or cell death by blocking cell cycle progression through the S phase. Cell Growth Differ. 10, 435-446.
95. Hellner, K., Munger, K., 2011. Human papillomaviruses as therapeutic targets in human cancer. J. Clin. Oncol. 29, 1785-1794.
96. Hirsch, H.H., Kardas, P., Kranz, D., Leboeuf, C., 2013. The human JC polyomavirus (JCPyV): virological background and clinical implications. APMIS 121, 685-727.
97. Ho, H.T., Woods, K.L., Bronson, J.J., De Boeck, H., Martin, J.C., Hitchcock, M.J., 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol. 41, 197-202.
98. Hostetler, K.Y., Rought, S., Aldern, K.A., Trahan, J., Beadle, J.R., Corbeil, J., 2006. Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Mol. Cancer Ther. 5, 156-159.
99. Howie, H.L., Katzenellenbogen, R.A., Galloway, D.A., 2009. Papillomavirus E6 proteins. Virology 384, 324-334.
100. Jiang, M., Abend, J.R., Johnson, S.F., Imperiale, M.J., 2009. The role of polyomaviruses in human disease. Virology 384, 266-273.
101. Johne, R., Buck, C.B., Allander, T., Atwood, W.J., Garcea, R.L., Imperiale, M.J., Major, E.O., Ramqvist, T., Norkin, L.C., 2011. Taxonomical developments in the family Polyomaviridae. Arch. Virol. 156, 1627-1634.
102. Johnson, J.A., Gangemi, J.D., 1999. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Antimicrob. Agents Chemother. 43, 1198-1205.
103. Johnson, J.A., Gangemi, J.D., 2003. Alpha interferon augments cidofovir's antiviral and antiproliferative activities. Antimicrob. Agents Chemother. 47, 2022-2026.
104. Kaibuchi-Noda, K., Yokota, K., Matsumoto, T., Sawada, M., Sakakibara, A., Kono, M., Tomita, Y., Watanabe, D., Fukumoto, H., Katano, H., Akiyama, M., 2011. Detection of Merkel cell polyomavirus in cutaneous squamous cell carcinoma before occurrence of Merkel cell carcinoma. J. Am. Acad. Dermatol. 65, 152-154.
105. Kazem, S., van der, M.E., Feltkamp, M.C., 2013. The trichodysplasia spinulosa-associated polyomavirus: virological background and clinical implications. APMIS 121, 770-782.
106. Kazem, S., van der, M.E., Kooijman, S., Rosenberg, A.S., Hughey, L.C., Browning, J.C., Sadler, G., Busam, K., Pope, E., Benoit, T., Fleckman, P., de Vries, E., Eekhof, J.A., Feltkamp, M.C., 2012. Trichodysplasia spinulosa is characterized by active polyomavirus infection. J. Clin. Virol. 53, 225-230.
107. Khalil, H.S., Tummala, H., Chakarov, S., Zhelev, N., Lane, P.L., 2012. Targeting ATM pathway for therapeutic intervention in cancer. BioDiscovery. http://dx.doi.org/10.7750/BioDiscovery.1.3.
108. Khalili, K., White, M.K., Sawa, H., Nagashima, K., Safak, M., 2005. The agnoprotein of polyomaviruses: a multifunctional auxiliary protein. J. cell. Physiol. 204, 1-7.
109. Koonsaeng, S., Verschraegen, C., Freedman, R., Bossens, M., Kudelka, A., Kavanagh, J., Sittisomwong, T., DeClercq, E., Snoeck, R., 2001. Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. J. Med. Virol. 64, 195-198.
110. Koskenvuo, M., Dumoulin, A., Lautenschlager, I., Auvinen, E., Mannonen, L., Anttila, V.J., Jahnukainen, K., Saarinen-Pihkala, U.M., Hirsch, H.H., 2013. BK polyomavirus-associated hemorrhagic cystitis among pediatric allogeneic bone marrow transplant recipients: treatment response and evidence for nosocomial transmission. J. Clin. Virol. 56, 77-81.
111. Kralund, H.H., Broesby-Olsen, S., Bistrup, C., Lorentzen, H.F., 2011. Substantial effect of topical cidofovir 1% on recalcitrant warts in a renal-transplanted adolescent: a case report. Transplantation 91, 52-54.
112. Kramata, P., Downey, K.M., Paborsky, L.R., 1998. Incorporation and excision of 9-(2-phosphonylmethoxyethyl)guanine (PMEG) by DNA polymerase delta and epsilon in vitro. J. Biol. Chem. 273, 21966-21971.
113. Kramata, P., Votruba, I., Otova, B., Holy, A., 1996. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol. Pharmacol. 49, 1005-1011.
114. Kreider, J.W., Balogh, K., Olson, R.O., Martin, J.C., 1990. Treatment of latent rabbit and human papillomavirus infections with 9-(2-phosphonylmethoxy)ethylguanine (PMEG). Antiviral Res. 14, 51-58.
115. Ksiazek, J., Prager, J.D., Sun, G.H., Wood, R.E., Arjmand, E.M., 2011. Inhaled cidofovir as an adjuvant therapy for recurrent respiratory papillomatosis. Otolaryngol. Head Neck Surg. 144, 639-641.
116. Kuo, S.R., Liu, J.S., Broker, T.R., Chow, L.T., 1994. Cell-free replication of the human papillomavirus DNA with homologous viral E1 and E2 proteins and human cell extracts. J. Biol. Chem. 269, 24058-24065.
117. Kuypers, D.R., 2012. Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat. Rev. Nephrol. 8, 390-402.
118. Kuypers, D.R., Vandooren, A.K., Lerut, E., Evenepoel, P., Claes, K., Snoeck, R., Naesens, L., Vanrenterghem, Y., 2005. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am. J. Transplant. 5, 1997-2004.
119. Kwon, H.J., Kang, J.H., Lee, J.W., Chung, N.G., Kim, H.K., Cho, B., 2013. Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir: a single-center experience. Transpl. Infect. Dis. 15, 569-574.
120. Lebeau, I., Andrei, G., Krecmerova, M., De Clercq, E., Holy, A., Snoeck, R., 2007. Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains. Antimicrob. Agents Chemother. 51, 2268-2273.
121. Leemans, C.R., Braakhuis, B.J., Brakenhoff, R.H., 2011. The molecular biology of head and neck cancer. Nat. Rev. Cancer 11, 9-22.
122. Liekens, S., Andrei, G., Vandeputte, M., De Clercq, E., Neyts, J., 1998. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res. 58, 2562-2567.
123. Liekens, S., Gijsbers, S., Vanstreels, E., Daelemans, D., De Clercq, E., Hatse, S., 2007. The nucleotide analog cidofovir suppresses basic fibroblast growth factor (FGF2) expression and signaling and induces apoptosis in FGF2-overexpressing endothelial cells. Mol. Pharmacol. 71, 695-703.
124. Liekens, S., Verbeken, E., De Clercq, E., Neyts, J., 2001. Potent inhibition of hemangiosarcoma development in mice by cidofovir. Int. J. Cancer 92, 161-167.
125. Lin, B.Y., Ma, T., Liu, J.S., Kuo, S.R., Jin, G., Broker, T.R., Harper, J.W., Chow, L.T., 2000. HeLa cells are phenotypically limiting in cyclin E/CDK2 for efficient human papillomavirus DNA replication. J. Biol. Chem. 275, 6167-6174.
126. Lin, B.Y., Makhov, A.M., Griffith, J.D., Broker, T.R., Chow, L.T., 2002. Chaperone proteins abrogate inhibition of the human papillomavirus (HPV) E1 replicative helicase by the HPV E2 protein. Mol. Cell. Biol. 22, 6592-6604.
127. Liu, J.S., Kuo, S.R., Broker, T.R., Chow, L.T., 1995. The functions of human papillomavirus type 11 E1, E2, and E2C proteins in cell-free DNA replication. J. Biol. Chem. 270, 27283-27291.
128. Mackey, M.C., 2012. Intravesicular cidofovir for the treatment of polyomavirus-associated hemorrhagic cystitis. Ann. Pharmacother. 46, 442-446.
129. Maginnis, M.S., Stroh, L.J., Gee, G.V., O'Hara, B.A., Derdowski, A., Stehle, T., Atwood, W.J., 2013. Progressive multifocal leukoencephalopathy-associated mutations in the JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding. MBio 4, 00247.
130. Manzo-Merino, J., Thomas, M., Fuentes-Gonzalez, A.M., Lizano, M., Banks, L., 2013. HPV E6 oncoprotein as a potential therapeutic target in HPV related cancers. Expert Opin. Ther. Targets 17, 1357-1368.
131. Matteelli, A., Beltrame, A., Graifemberghi, S., Forleo, M.A., Gulletta, M., Ciravolo, G., Tedoldi, S., Casalini, C., Carosi, G., 2001. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex. Transm. Dis. 28, 343-346.
132. Maximova, N., Granzotto, M., Kiren, V., Zanon, D., Comar, M., 2013. First description of Merkel Cell polyomavirus DNA detection in a patient with Stevens-Johnson syndrome. J. Med. Virol. 85, 918-923.
133. McBride, A.A., 2013. The papillomavirus E2 proteins. Virology 445, 57-79.
134. McLaughlin-Drubin, M.E., Munger, K., 2009. Oncogenic activities of human papillomaviruses. Virus Res. 143, 195-208.
135. Mertlikova-Kaiserova, H., Nejedla, M., Holy, A., Votruba, I., 2012. Involvement of MAP kinases in the cytotoxicity of acyclic nucleoside phosphonates. Anticancer Res. 32, 497-501.
136. Mertlikova-Kaiserova, H., Rumlova, M., Tloustova, E., Prochazkova, E., Holy, A., Votruba, I., 2011. Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG. Biochem. Pharmacol. 82, 131-138.
137. Mikolajczak, S., Quante, G., Weissenborn, S., Wafaisade, A., Wieland, U., Luers, J.C., Klussmann, J.P., Beutner, D., 2012. The impact of cidofovir treatment on viral loads in adult recurrent respiratory papillomatosis. Eur. Arch. Otorhinolaryngol. 269, 2543-2548.
138. Miller, D.L., Puricelli, M.D., Stack, M.S., 2012. Virology and molecular pathogenesis of HPV (human papillomavirus)-associated oropharyngeal squamous cell carcinoma. Biochem. J. 443, 339-353.
139. Momper, J.D., Zhao, Y., Shapiro, R., Schonder, K.S., Gao, Y., Randhawa, P.S., Venkataramanan, R., 2013. Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection. Transpl. Infect. Dis. 15, 34-41.
140. Moody, C.A., Laimins, L.A., 2010. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10, 550-560.
141. Moore, P.S., Chang, Y., 2010. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat. Rev. Cancer 10, 878-889.
142. Naesens, L., Hatse, S., Segers, C., Verbeken, E., De Clercq, E., Waer, M., Balzarini, J., 1999. 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: a novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats. Oncol. Res. 11, 195-203.
143. Naess, H., Glad, S., Storstein, A., Rinaldo, C.H., Mork, S.J., Myhr, K.M., Hirsch, H., 2010. Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurol. 10, 32.
144. Neu, U., Allen, S.A., Blaum, B.S., Liu, Y., Frank, M., Palma, A.S., Stroh, L.J., Feizi, T., Peters, T., Atwood, W.J., Stehle, T., 2013. A structure-guided mutation in the major capsid protein retargets BK polyomavirus. PLoS Pathog. 9, e1003688.
145. Nor, R.N., Yusof, R., Watson, R.J., 2011. Disruption of repressive p130-DREAM complexes by human papillomavirus 16 E6/E7 oncoproteins is required for cell-cycle progression in cervical cancer cells. J. Gen. Virol. 92, 2620-2627.
146. Nor, R.N., Yusof, R., Watson, R.J., 2013. Disruption of pocket protein dream complexes by E7 proteins of different types of human papillomaviruses. Acta Virol. 57, 447-451.
147. Olthof, N.C., Straetmans, J.M., Snoeck, R., Ramaekers, F.C., Kremer, B., Speel, E.J., 2012. Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go? Rev. Med. Virol. 22, 88-105.
148. Osorio, S., de la, C.R., Golbano, N., Marti, E., Fedele, C.G., Nieto, S., Manzanares, R., Fernandez-Ranada, J.M., 2002. Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir. Bone Marrow Transplant 30, 963-966.
149. Otova, B., Francova, K., Franek, F., Koutnik, P., Votruba, I., Holy, A., Sladka, M., Schramlova, J., 1999. 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP)-a potential drug against hematological malignancies-induces apoptosis. Anticancer Res. 19, 3173-3182.
150. Otova, B., Hrdy, J., Votruba, I., Holy, A., 2009. In vivo modulation of angiogenic gene expression by acyclic nucleoside phosphonates PMEDAP and PMEG. Anticancer Res. 29, 1295-1302.
151. Owczarczyk, K., Hilker, R., Brunn, A., Hallek, M., Rubbert, A., 2007. Progressive multifocal leucoencephalopathy in a patient with sarcoidosis - successful treatment with cidofovir and mirtazapine. Rheumatology (Oxford) 46, 888-890.
152. Pantulu, N.D., Pallasch, C.P., Kurz, A.K., Kassem, A., Frenzel, L., Sodenkamp, S., Kvasnicka, H.M., Wendtner, C.M., Zur, H.A., 2010. Detection of a novel truncating Merkel cell polyomavirus large T antigen deletion in chronic lymphocytic leukemia cells. Blood 116, 5280-5284.
153. Park, J.H., Ryoo, S., Noh, H.J., Seo, J.M., Kang, H.H., Shin, J.S., Seo, S.W., Na, D.L., 2011. Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. Case Rep. Neurol. 3, 258-262.
154. Pastrana, D.V., Fitzgerald, P.C., Phan, G.Q., Raiji, M.T., Murphy, P.M., McDermott, D.H., Velez, D., Bliskovsky, V., McBride, A.A., Buck, C.B., 2013. A divergent variant of the eleventh human polyomavirus species, saint louis polyomavirus. Genome Announc. 1.
155. Pim, D., Banks, L., 2010. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs. low-risk human papillomaviruses. APMIS 118, 471-493.
156. Pisarev, V.M., Lee, S.H., Connelly, M.C., Fridland, A., 1997. Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. Mol. Pharmacol. 52, 63-68.
157. Preiser, W., Kapur, N., Snoeck, R., Groves, R.W., Brink, N.S., 2000. No apparent effect of cidofovir in epidermodysplasia verruciformis. J. Clin. Virol. 16, 55-57.
158. Raghava, S., Giorda, K.M., Romano, F.B., Heuck, A.P., Hebert, D.N., 2011. The SV40 late protein VP4 is a viroporin that forms pores to disrupt membranes for viral release. PLoS Pathog. 7, e1002116.
159. Raghava, S., Giorda, K.M., Romano, F.B., Heuck, A.P., Hebert, D.N., 2013. SV40 late protein VP4 forms toroidal pores to disrupt membranes for viral release. Biochemistry 52, 3939-3948.
160. Rector, A., Van Ranst, M., 2013. Animal papillomaviruses. Virology 445, 213-223.
161. Redondo, P., Idoate, M., Galofre, J.C., Solano, T., 2000. Cidofovir inhibits growth of B16 melanoma cells in vivo. Br. J. Dermatol. 143, 741-748.
162. Reiser, H., Wang, J., Chong, L., Watkins, W.J., Ray, A.S., Shibata, R., Birkus, G., Cihlar, T., Wu, S., Li, B., Liu, X., Henne, I.N., Wolfgang, G.H., Desai, M., Rhodes, G.R., Fridland, A., Lee, W.A., Plunkett, W., Vail, D., Thamm, D.H., Jeraj, R., Tumas, D.B., 2008. GS-9219 - a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin. Cancer Res. 14, 2824-2832.
163. Reisinger, D.M., Shiffer, J.D., Cognetta Jr., A.B., Chang, Y., Moore, P.S., 2010. Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma. J. Am. Acad. Dermatol. 63, 400-403.
164. Rietbergen, M.M., Leemans, C.R., Bloemena, E., Heideman, D.A., Braakhuis, B.J., Hesselink, A.T., Witte, B.I., Baatenburg de Jong, R.J., Meijer, C.J., Snijders, P.J., Brakenhoff, R.H., 2013. Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int. J. Cancer 132, 1565-1571.
165. Rinaldo, C.H., Gosert, R., Bernhoff, E., Finstad, S., Hirsch, H.H., 2010. 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob. Agents Chemother. 54, 4714-4722.
166. Ripellino, P., Comi, C., Mula, M., Varrasi, C., Conconi, A., Stecco, A., Brustia, D., Nasuelli, N., Savio, K., De Paoli, L., Cantello, R., Gaidano, G., Monaco, F., 2011. Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. BMJ Case Rep. 2011.
167. Rodig, S.J., Cheng, J., Wardzala, J., DoRosario, A., Scanlon, J.J., Laga, A.C., Martinez-Fernandez, A., Barletta, J.A., Bellizzi, A.M., Sadasivam, S., Holloway, D.T., Cooper, D.J., Kupper, T.S., Wang, L.C., DeCaprio, J.A., 2012. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J. Clin. Invest. 122, 4645-4653.
168. Rollison, D.E., Giuliano, A.R., Messina, J.L., Fenske, N.A., Cherpelis, B.S., Sondak, V.K., Roetzheim, R.G., Iannacone, M.R., Michael, K.M., Gheit, T., Waterboer, T., Tommasino, M., Pawlita, M., 2012. Case-control study of Merkel cell polyomavirus infection and cutaneous squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 21, 74-81.
169. Rose, W.C., Crosswell, A.R., Bronson, J.J., Martin, J.C., 1990. In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phosphonate nucleotide analogues. J. Natl Cancer Inst. 82, 510-512.
170. Sapp, M., Day, P.M., 2009. Structure, attachment and entry of polyoma- and papillomaviruses. Virology 384, 400-409.
171. Savona, M.R., Newton, D., Frame, D., Levine, J.E., Mineishi, S., Kaul, D.R., 2007. Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant. 39, 783-787.
172. Shuda, M., Feng, H., Kwun, H.J., Rosen, S.T., Gjoerup, O., Moore, P.S., Chang, Y., 2008. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc. Natl. Acad. Sci. U.S.A. 105, 16272-16277.
173. Snoeck, R., Bossens, M., Parent, D., Delaere, B., Degreef, H., Van Ranst, M., Noel, J.C., Wulfsohn, M.S., Rooney, J.F., Jaffe, H.S., De Clercq, E., 2001. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin. Infect. Dis. 33, 597-602.
174. Snoeck, R., De Clercq, E., 2002. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr. Opin. Investig. Drugs 3, 1561-1566.
175. Snoeck, R., Noel, J.C., Muller, C., De Clercq, E., Bossens, M., 2000. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J. Med. Virol. 60, 205-209.
176. Snoeck, R., Van Ranst, M., Andrei, G., De Clercq, E., De Wit, S., Poncin, M., Clumeck, N., 1995. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N. Engl. J. Med. 333, 943-944.
177. Snoeck, R., Wellens, W., Desloovere, C., Van Ranst, M., Naesens, L., De Clercq, E., Feenstra, L., 1998. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J. Med. Virol. 54, 219-225.
178. Spurgeon, M.E., Lambert, P.F., 2013. Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology 435, 118-130.
179. Stanley, M.A., 2012. Epithelial cell responses to infection with human papillomavirus. Clin. Microbiol. Rev. 25, 215-222.
180. Stanley, M.A., Pett, M.R., Coleman, N., 2007. HPV: from infection to cancer. Biochem. Soc. Trans. 35, 1456-1460.
181. Stern, P.L., van der Burg, S.H., Hampson, I.N., Broker, T.R., Fiander, A., Lacey, C.J., Kitchener, H.C., Einstein, M.H., 2012. Therapy of human papillomavirus-related disease. Vaccine 30 (Suppl. 5), F71-F82.
182. Stier, E.A., Goldstone, S.E., Einstein, M.H., Jay, N., Berry, J.M., Wilkin, T., Lee, J.Y., Darragh, T.M., Da Costa, M., Panther, L., Aboulafia, D., Palefsky, J.M., 2013. Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS 27, 545-551.
183. Stoler, M.H., Rhodes, C.R., Whitbeck, A., Wolinsky, S.M., Chow, L.T., Broker, T.R., 1992. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23, 117-128.
184. Stragier, I., Snoeck, R., De Clercq, E., Van Den Oord, J.J., Van Ranst, M., De Greef, H., 2002. Local treatment of HPV-induced skin lesions by cidofovir. J. Med. Virol. 67, 241-245.
185. Suzuki, T., Orba, Y., Okada, Y., Sunden, Y., Kimura, T., Tanaka, S., Nagashima, K., Hall, W.W., Sawa, H., 2010. The human polyoma JC virus agnoprotein acts as a viroporin. PLoS Pathog. 6, e1000801.
186. Syrjanen, S., 2010. Current concepts on human papillomavirus infections in children. APMIS 118, 494-509.
187. Thamm, D.H., Vail, D.M., Kurzman, I.D., Babusis, D., Ray, A.S., Sousa-Powers, N., Tumas, D.B., 2014. GS-9219/VDC-1. BMC Vet. Res. 10, 30.
188. Tjon Pian Gi, R.E., Dietz, A., Djukic, V., Eckel, H.E., Friedrich, G., Golusinski, W., Hantzakos, A., Lawson, G., Remacle, M., Rihkanen, H., Dikkers, F.G., 2012. Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide(R)). Eur. Arch. Otorhinolaryngol. 269, 361-362.
189. Tjon Pian Gi, R.E., Ilmarinen, T., van den Heuvel, E.R., Aaltonen, L.M., Andersen, J., Brunings, J.W., Chirila, M., Dietz, A., Ferran, V.F., Friedrich, G., de Gier, H.H., Golusinski, W., Graupp, M., Hantzakos, A., Horcasitas, R., Jackowska, J., Koelmel, J.C., Lawson, G., Lindner, F., Remacle, M., Sittel, C., Weichbold, V., Wierzbicka, M., Dikkers, F.G., 2013. Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients. Eur. Arch. Otorhinolaryngol. 270, 1679-1687.
190. Topalis, D., Andrei, G., Snoeck, R., 2013. The large tumor antigen: a "Swiss Army knife" protein possessing the functions required for the polyomavirus life cycle. Antiviral Res. 97, 122-136.
191. Topalis, D., Lebeau, I., Krecmerova, M., Andrei, G., Snoeck, R., 2011. Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells. Antimicrob. Agents Chemother. 55, 1961-1967.
192. Trakselis, M.A., Graham, B.W., 2012. Biochemistry: molecular hurdles cleared with ease. Nature 492, 195-197.
193. Tristram, A., Fiander, A., 2005. Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecol. Oncol. 99, 652-655.
194. Tsai, B., Qian, M., 2010. Cellular entry of polyomaviruses. Curr. Top. Microbiol. Immunol. 343, 177-194.
195. Vail, D.M., Thamm, D.H., Reiser, H., Ray, A.S., Wolfgang, G.H., Watkins, W.J., Babusis, D., Henne, I.N., Hawkins, M.J., Kurzman, I.D., Jeraj, R., Vanderhoek, M., Plaza, S., Anderson, C., Wessel, M.A., Robat, C., Lawrence, J., Tumas, D.B., 2009. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin. Cancer Res. 15, 3503-3510.
196. Valiaeva, N., Trahan, J., Aldern, K.A., Beadle, J.R., Hostetler, K.Y., 2010. Antiproliferative effects of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine against Me-180 human cervical cancer cells in vitro and in vivo. Chemotherapy 56, 54-59.
197. van Boheemen, S., Jones, T., Muhlemann, B., Feltkamp, M.C., Fouchier, R.A., Hajdarbegovic, E., 2014. Cidofovir gel as treatment of follicular spicules in multiple myeloma. JAMA Dermatol. [Epub ahead of print].
198. Van Cutsem, E., Snoeck, R., Van Ranst, M., Fiten, P., Opdenakker, G., Geboes, K., Janssens, J., Rutgeerts, P., Vantrappen, G., De Clercq, E., 1995. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J. Med. Virol. 45, 230-235.
199. van der Meijden, E., Janssens, R.W., Lauber, C., Bouwes Bavinck, J.N., Gorbalenya, A.E., Feltkamp, M.C., 2010. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog. 6, e1001024.
200. Van Ghelue, M., Khan, M.T., Ehlers, B., Moens, U., 2012. Genome analysis of the new human polyomaviruses. Rev. Med. Virol. 22, 354-377.
201. Van Pachterbeke, C., Bucella, D., Rozenberg, S., Manigart, Y., Gilles, C., Larsimont, D., Vanden Houte, K., Reynders, M., Snoeck, R., Bossens, M., 2009. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebocontrolled study. Gynecol. Oncol. 115, 69-74.
202. Viallard, J.F., Lazaro, E., Ellie, E., Eimer, S., Camou, F., Caubet, O., Lafon, M.E., Fleury, H., Pellegrin, J.L., 2007. Improvement of progressive multifocal leukoencephalopathy after cidofovir therapy in a patient with a destructive polyarthritis. Infection 35, 33-36.
203. Viallard, J.F., Lazaro, E., Lafon, M.E., Pellegrin, J.L., 2005. Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma. Leuk. Lymphoma 46, 1659-1662.
204. Volker, H.U., Kraft, K., Arnold, E., Steinhoff, S., Kolios, G., Sommer, S., 2007. Progressive multifocal leukoencephalopathy developing in advanced pulmonal sarcoidosis. Clin. Neurol. Neurosurg. 109, 624-630.
205. Wanat, K.A., Holler, P.D., Dentchev, T., Simbiri, K., Robertson, E., Seykora, J.T., Rosenbach, M., 2012. Viral-associated trichodysplasia: characterization of a novel polyomavirus infection with therapeutic insights. Arch. Dermatol. 148, 219-223.
206. Wang, H.K., Duffy, A.A., Broker, T.R., Chow, L.T., 2009. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev. 23, 181-194.
207. Wang, Q., Griffin, H., Southern, S., Jackson, D., Martin, A., McIntosh, P., Davy, C., Masterson, P.J., Walker, P.A., Laskey, P., Omary, M.B., Doorbar, J., 2004. Functional analysis of the human papillomavirus type 16 E1=E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization. J. Virol. 78, 821-833.
208. Wetherill, L.F., Holmes, K.K., Verow, M., Muller, M., Howell, G., Harris, M., Fishwick, C., Stonehouse, N., Foster, R., Blair, G.E., Griffin, S., Macdonald, A., 2012. High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors. J. Virol. 86, 5341-5351.
209. White, M.K., Gordon, J., Khalili, K., 2013. The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology. PLoS Pathog. 9, e1003206.
210. Wolfgang, G.H., Shibata, R., Wang, J., Ray, A.S., Wu, S., Doerrfler, E., Reiser, H., Lee, W.A., Birkus, G., Christensen, N.D., Andrei, G., Snoeck, R., 2009. GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions. Antimicrob. Agents Chemother. 53, 2777-2784.
211. Xiong, X., Smith, J.L., Chen, M.S., 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41, 594-599.
212. Xiong, X., Smith, J.L., Kim, C., Huang, E.S., Chen, M.S., 1996. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 51, 1563-1567.
213. Yang, Y., Zhao, X., Chen, W., Gao, Z., Liu, A., Guo, J., Yan, Z., Dou, Y., Wang, H., Li, Y., 2010. Effects of cidofovir on human papillomavirus-positive cervical cancer cells xenografts in nude mice. Oncol. Res. 18, 519-527.
214. Yardimci, H., Wang, X., Loveland, A.B., Tappin, I., Rudner, D.Z., Hurwitz, J., van Oijen, A.M., Walter, J.C., 2012. Bypass of a protein barrier by a replicative DNA helicase. Nature 492, 205-209.
215. Yu, G., Greninger, A.L., Isa, P., Phan, T.G., Martinez, M.A., de la Luz, S.M., Contreras, J.F., Santos-Preciado, J.I., Parsonnet, J., Miller, S., DeRisi, J.L., Delwart, E., Arias, C.F., Chiu, C.Y., 2012. Discovery of a novel polyomavirus in acute diarrheal samples from children. PLoS One 7, e49449.
216. Yugawa, T., Kiyono, T., 2009. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev. Med. Virol. 19, 97-113.
217. zur Hausen, H., 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2, 342-350.